A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will evaluate the effect of high-dose, intermittent sunitinib
versus treatment with lomustine in patients with recurrent glioblastoma multiforme. The
investigators hypothesize that sunitinib, when given in a high-dose, intermittent schedule,
will achieve adequate concentration levels in the tumor and will, besides its anti-angiogenic
properties, inhibit gliomagenesis by inhibition of multiple kinases.